Truist Securities Analyst Reaffirms Positive Outlook on Keros Therapeutics with 100 Price Target
On March 13, 2024, Truist Securities analyst Srikripa Devarakonda reaffirmed a positive outlook on Keros Therapeutics (NASDAQ: KROS), maintaining a ...
On March 13, 2024, Truist Securities analyst Srikripa Devarakonda reaffirmed a positive outlook on Keros Therapeutics (NASDAQ: KROS), maintaining a ...
StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.